Business Wire

CA-STARCITY

23.12.2020 17:02:14 CET | Business Wire | Press release

Share
Starcity Is Launching Invest.starcity.com in Partnership With Republic Real Estate to Allow Accredited Investors to Back Coliving Real Estate Development Projects

Starcity, one of the fastest-growing technology enabled real estate owners and operators, announced today the launch of invest.starcity.com . This first of its kind investment platform allows accredited investors the opportunity to back Starcity development projects.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20201223005265/en/

"We are thrilled to launch invest.starcity.com , so investors of all kinds have the opportunity to back Starcity developments. Typically, large-scale institutional investments are reserved for closed-door dealings, and we're excited to open these deals up to democratize access for more people," said Jon Dishotsky, CEO and co-founder of Starcity.

The first project will be Starcity Minna, a fully approved, 16-story, 270 unit, highrise in the South of Market (SoMa) district of San Francisco. Starcity will operate the 122,845 gross square feet development as a furnished residential community targeting middle and low-income residents of San Francisco with a convenient, value-oriented, and highly amenitized residential lifestyle offering.

"Despite the fall in rents in San Francisco this past year, the city remains largely out of reach for working-class professionals. Very few individuals can afford a $3,000 to $4,000 apartment, and we're excited to deliver units that start in the $900-$1,000 range. This level of affordability has rarely been achieved in San Francisco. Furthermore, major investors and occupiers like Amazon, Blackstone, Google, KKR, Starwood, and others have announced investment initiatives into San Francisco during the pandemic, and Brookfield is going vertical on projects right next door to Minna, so the time is right. And despite noise in the headlines, San Francisco has been a consistently above-market return investment geography due to the supply constraints and demand drivers," said Mo Sakrani, Chief Investment Officer and co-founder of Starcity.

Starcity Minna will comprise 15 residential levels over a welcoming ground floor lobby and event space attached to an outdoor patio, as well as a bike repair and storage facility. Each residential level (FL 2-16) hosts 18 private units with ensuite bathrooms and features a 1,000 square feet amenity space that includes a chef's-style kitchen and dining area, lounge, and media area with expansive city views. The building is topped by a large landscaped rooftop terrace, offering panoramic views of San Francisco.

Starcity Minna will consist of steel modules over a concrete ground-floor podium, tied-together with a concrete elevator core. Four primary module types will make up the private units, corridors, common areas, and stairs. Each module will arrive fully outfitted with furnishings, bathroom and kitchen fixtures, piping, and wiring.

Modular construction is well suited for Starcity Minna for two main reasons. First, San Francisco is one of the most expensive cities to build in globally, and modular construction shifts those costs to an off-site factory. Second, the standardized unit layout is conducive to manufacturing.

"San Francisco remains one of the strongest apartment rental markets in the country. We are delighted to provide access for individual investors into a well-located project poised to capitalize on the city’s next wave of growth and appreciation through technology powered by the Republic platform. Real estate is an $8.9 trillion market, and it's time for everybody to own a piece of it,” said Janine Yorio, Head of Real Estate at Republic.

With this new offering Starcity is reimagining the entire spectrum of real estate:

  • On the investment side by allowing people access to build wealth.
  • On the housing side by making living in cities accessible.
  • On the construction side, by exploring modular to bring the cost of construction down.

This template should create a path for major affordable housing in any city that has income inequality that has been further exacerbated by the pandemic. Real estate has long been a stodgy investment industry, designed to keep the main street investor out — Starcity aims to change that with this launch.

Starcity is one of the leading coliving companies and operates over 1,500 units globally, with over 3,000 units in its development and operations pipeline throughout North America and Western Europe and over 10,000 units in negotiations. Starcity is backed by Y Combinator, NEA, Social Capital, Tribe Capital, Bullpen Capital, Deciens, and Industry Ventures.

Starcity is conducting a Rule 506(c) offering solely to accredited investors. Republic Real Estate has provided the technology to enable Invest.starcity.com.

Social Media:

https://facebook.com/starcity

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release

Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release

Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s

Pivotal Trial Data for EP0031 (A400), a Next-Generation Selective RET Inhibitor (SRI), in RET Positive Advanced NSCLC, to be Presented at ASCO 202622.5.2026 11:18:00 CEST | Press release

Ellipses Pharma (“Ellipses”), a global oncology drug development company with a pipeline of innovative programmes, announced today that its partner, Kelun-Biotech, is presenting pivotal trial data for EP0031/A400, for the potential treatment of RET-fusion positive Non-Small Cell Lung Cancer (NSCLC), at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, May 29 to June 2. Efficacy and safety of lunbotinib (A400/EP0031), a next-generation selective RET inhibitor (SRI), from a pivotal phase Ⅱ study in patients with advanced RET-fusion positive non-small cell lung cancer (NSCLC), will be presented as an oral presentation scheduled on May 29, 2026, 14:36-14:48 local time (Abstract #8505: Lung Cancer – Non-Small Cell Metastatic). The oral presentation of these data at the prestigious ASCO annual meeting, represents another major milestone in the global development of EP0031/A400 as a next generation SRI. The data were generated in Kelun-Biotech’s Phase 2 study (NCT0

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye